0001438533-24-000016.txt : 20240424 0001438533-24-000016.hdr.sgml : 20240424 20240424160522 ACCESSION NUMBER: 0001438533-24-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240424 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240424 DATE AS OF CHANGE: 20240424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262383102 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 24870544 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 8-K 1 tvtx-20240424.htm 8-K tvtx-20240424
0001438533false00014385332024-04-242024-04-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
___________________________
Current Report
Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2024
___________________________
TRAVERE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
___________________________

Delaware
 
001-36257
 
27-4842691
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130
(Address of Principal Executive Offices, including Zip Code)

(888) 969-7879
(Registrant’s Telephone Number, including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per share
TVTX
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Item 8.01    Other Events.
On April 24, 2024, Travere Therapeutics, Inc. (the “Company”) and CSL Vifor announced that the European Commission has granted conditional marketing authorization (“CMA”) for FILSPARI® (sparsentan) for the treatment of adults with primary IgA nephropathy (“IgAN”) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

The European Commission's decision follows the positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) in February 2024, based on results from the pivotal Phase 3 PROTECT Study of FILSPARI in IgAN.

Sparsentan is currently marketed in the U.S. under accelerated approval granted by the U.S. Food and Drug Administration under the brand name FILSPARI® to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.

In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand.

CSL Vifor expects to launch FILSPARI in the first European markets in the second half of 2024.

Forward-Looking Statements

This Current Report on Form 8-K contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements regarding the approval process and expectations for the launch of FILSPARI in European markets and the anticipated timing thereof. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the regulatory review and approval process, as well as risks and uncertainties associated with the Company’s business and finances in general, the success of its commercial products and risks and uncertainties associated with the Company’s preclinical and clinical stage pipeline. Specifically, the Company faces risks associated with the planned launch of FILSPARI in certain European markets and the anticipated timing thereof, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, as well as risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI. The risks and uncertainties the Company faces with respect to its preclinical and clinical stage pipeline include risk that the Company’s clinical candidates will not be found to be safe or effective and that current or anticipated future clinical trials will not proceed as planned. Specifically, the Company faces risks related to the timing and potential outcome of the FDA’s potential acceptance for filing and review of the sNDA submission for full approval of FILSPARI in IgAN. There is no guarantee that the FDA will accept the sNDA submission for filing or that regulators will grant full approval of sparsentan for IgAN. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations.

In addition, such risks and uncertainties may include those described in the Company’s filings with the SEC, including under the “Risk Factors” heading of the Company’s annual report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 20, 2024, and other filings with the SEC, which are also available at the Company’s website (www.travere.com) under “Investors & Media”. You are cautioned not to place undue reliance on any forward-looking statements as there are important factors that could cause actual results to differ materially from those in any forward-looking statements, many of which are beyond the Company’s control. Except to the extent required by law, the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Item 9.01    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    TRAVERE THERAPEUTICS, INC.
    
Dated: April 24, 2024   By:/s/ Eric Dube
      Name:Eric Dube
Title:Chief Executive Officer


 EX-101.SCH 2 tvtx-20240424.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 tvtx-20240424_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 4 tvtx-20240424_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 24, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 24, 2024
Entity Registrant Name TRAVERE THERAPEUTICS, INC.
Entity Central Index Key 0001438533
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-36257
Entity Tax Identification Number 27-4842691
Entity Address, Address Line One 3611 Valley Centre Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 888
Local Phone Number 969-7879
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol TVTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.travere.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tvtx-20240424.htm tvtx-20240424.xsd tvtx-20240424_lab.xml tvtx-20240424_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tvtx-20240424.htm": { "nsprefix": "tvtx", "nsuri": "http://www.travere.com/20240424", "dts": { "inline": { "local": [ "tvtx-20240424.htm" ] }, "schema": { "local": [ "tvtx-20240424.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tvtx-20240424_lab.xml" ] }, "presentationLink": { "local": [ "tvtx-20240424_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.travere.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tvtx-20240424.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tvtx-20240424.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.travere.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001438533-24-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001438533-24-000016-xbrl.zip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end XML 16 tvtx-20240424_htm.xml IDEA: XBRL DOCUMENT 0001438533 2024-04-24 2024-04-24 0001438533 false 8-K 2024-04-24 TRAVERE THERAPEUTICS, INC. DE 001-36257 27-4842691 3611 Valley Centre Drive Suite 300 San Diego CA 92130 888 969-7879 false false false false Common Stock, par value $0.0001 per share TVTX NASDAQ false